Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Canelas Vng

661 clinical trials in Canelas Vng, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Canelas Vng at a glance
661
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

661 trials in Canelas Vng

Open in trial search

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Immunisation+3

Recruiting

SARS‑CoV‑2 spike protein vaccine and drug combination study in adults 60 years and older with COVID‑19 and influenza

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:TAK-019
  • Sponsor:Sanofi Vaccines US Inc.

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:LY4268989 adipic acid
  • Sponsor:Eli Lilly & Co.

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

A study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Apecotrep
  • Sponsor:Boehringer Ingelheim Espana S.A.

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Canelas Vng

What the registry says about research in the country

01 Cardiovascular Research

Clinical investigations focusing on atherosclerotic cardiovascular disease in patients with end-stage kidney disease, exploring innovative therapeutic approaches for this complex patient population.

  • Cardiovascular Outcomes
  • Inflammation Markers
  • Dialysis Patient Care

The research aims to assess treatment effectiveness through monitoring C-reactive protein levels in dialysis patients, potentially leading to improved cardiovascular outcomes in this high-risk group.

02 Nephrology Studies

Specialized research targeting patients with end-stage kidney disease undergoing maintenance dialysis, evaluating novel therapeutic interventions to address cardiovascular complications.

  • Renal Disease Management
  • Dialysis Therapy
  • Cardiovascular Risk

These trials explore intravenous treatments aimed at reducing inflammation markers and improving overall outcomes in dialysis patients.

03 Inflammatory Biomarkers

Investigation of inflammatory markers in cardiovascular disease, specifically focusing on high-sensitivity C-reactive protein as a key indicator in patients undergoing dialysis.

  • Biomarker Analysis
  • Inflammation Control
  • Treatment Response

The research evaluates various dosing strategies to optimize anti-inflammatory responses in patients with combined cardiovascular and kidney conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.